Overview

Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)

Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
A study to assess the efficacy and tolerability of ER (Extended Release) niacin/laropiprant versus placebo in Type 2 Diabetes Mellitus patients.
Phase:
Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Niacin
Niacinamide
Nicotinic Acids